ProCE Banner Activity

KEYNOTE-799: Phase II Trial of Pembrolizumab + Concurrent CRT in Unresectable Stage IIIA-C NSCLC

Slideset Download
Conference Coverage
Pembrolizumab + concurrent CRT followed by pembrolizumab consolidation conferred encouraging antitumor activity regardless of nonsquamous or squamous histology and PD-L1 expression levels.

Released: June 05, 2021

Expiration: June 04, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme